首页 > 最新文献

Hong Kong Journal of Nephrology最新文献

英文 中文
Concluding issue of the Hong Kong Journal of Nephrology 《香港肾脏学杂志》结束语
Pub Date : 2016-10-01 DOI: 10.1016/j.hkjn.2016.08.009
Fu-Keung Li
{"title":"Concluding issue of the Hong Kong Journal of Nephrology","authors":"Fu-Keung Li","doi":"10.1016/j.hkjn.2016.08.009","DOIUrl":"10.1016/j.hkjn.2016.08.009","url":null,"abstract":"","PeriodicalId":100611,"journal":{"name":"Hong Kong Journal of Nephrology","volume":"19 ","pages":"Page A8"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hkjn.2016.08.009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80789990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hong Kong Journal of Nephrology: Milestones from 1999 to 2016 香港肾脏病杂志:1999年至2016年的里程碑
Pub Date : 2016-10-01 DOI: 10.1016/j.hkjn.2016.08.002
Sydney C.W. Tang (Deputy Editor)
{"title":"Hong Kong Journal of Nephrology: Milestones from 1999 to 2016","authors":"Sydney C.W. Tang (Deputy Editor)","doi":"10.1016/j.hkjn.2016.08.002","DOIUrl":"10.1016/j.hkjn.2016.08.002","url":null,"abstract":"","PeriodicalId":100611,"journal":{"name":"Hong Kong Journal of Nephrology","volume":"19 ","pages":"Pages A2-A3"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hkjn.2016.08.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87577202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The last issue of the Hong Kong Journal of Nephrology 《香港肾脏学杂志》最后一期
Pub Date : 2016-10-01 DOI: 10.1016/j.hkjn.2016.08.004
Francis K.M. Wong
{"title":"The last issue of the Hong Kong Journal of Nephrology","authors":"Francis K.M. Wong","doi":"10.1016/j.hkjn.2016.08.004","DOIUrl":"10.1016/j.hkjn.2016.08.004","url":null,"abstract":"","PeriodicalId":100611,"journal":{"name":"Hong Kong Journal of Nephrology","volume":"19 ","pages":"Page A9"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hkjn.2016.08.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82420870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Until then, enjoy this issue! 在那之前,好好享受本期吧!
Pub Date : 2016-10-01 DOI: 10.1016/j.hkjn.2016.08.005
Siu-Ka Mak (Associate Editor)
{"title":"Until then, enjoy this issue!","authors":"Siu-Ka Mak (Associate Editor)","doi":"10.1016/j.hkjn.2016.08.005","DOIUrl":"10.1016/j.hkjn.2016.08.005","url":null,"abstract":"","PeriodicalId":100611,"journal":{"name":"Hong Kong Journal of Nephrology","volume":"19 ","pages":"Pages A4-A5"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hkjn.2016.08.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84284968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advance care planning for 600 Chinese patients with end-stage renal disease 600名中国终末期肾病患者的预先护理计划
Pub Date : 2016-10-01 DOI: 10.1016/j.hkjn.2016.04.001
Sze-Kit Yuen, Hay Ping Suen, Oi-Ling Kwok, Sai-Ping Yong, Man-Wah Tse

Background/purpose

There is increasing recognition of the need to integrate advance care planning (ACP) into end-stage renal disease (ESRD) care with attention to medical, ethical, psychosocial, and spiritual issues but publications comparing patients who chose renal replacement therapy (RRT) and renal palliative care (RPC) is scarce. We here share our experience on ACP for ESRD patients in a center with renal replacement and palliative programs in place.

Methods

From June 2006 to December 2011, ESRD patients were empowered to make an informed choice of future medical care in a structured ACP that was emphasized to be an ongoing process. Patients who opted for RRT and RPC would be followed up at the predialysis clinic and the one-stop multidisciplinary RPC clinic, respectively. This was a single-center study in a secondary care hospital. A total of 600 patients (265 RRT, 335 RPC) were enrolled and followed up over a median of 782 days.

Results

The majority of patients and relatives declined dialysis because of perceived physical burden. Only 1.6% of palliative care patients changed their decision and commenced dialysis. Baseline characteristics differed between patients who chose RRT or RPC. Survival declined according to the modified Charlson Comorbidity Index scores. Older age, mental incompetence, hyperlipidemia, high modified Charlson Comorbidity Index, low estimated glomerular filtration rate, and low albumin were important independent predictors of poor survival. Factors affecting the ACP decision were discussed in the Chinese culture context.

Conclusion

A structured ACP could empower the patient to make an informed decision on the management of ESRD.

背景

於未期腎病患者的照顧中加入關注身心社靈和倫理問題的預設照顧計劃(ACP)受到日益重視,但有關比較接受腎替代療法和接受腎臟紓緩治療文獻討論為數不多。作為同時提供腎透析服務以及腎臟紓緩治療的部門,本文旨在分享我們為未期腎病者討論預計照顧計劃的經驗。

方法

自二零零六年六月至二零一零五月間,透過有組織的預設照顧計劃討論,未期腎病患者會被鼓勵就未來的治療計劃作出知情選擇。選擇腎透析和腎臟紓緩治療的病人會分別於透析預備門診和一站式跨科際腎臟紓緩治療門診去覆診。本研究於一家二級醫院進行。總共有六百病人參與此研究,當中265名接受腎透析,335名接受腎臟紓緩治療,其中位跟進日數為782日。

結果

大部份病人和家屬之所以拒絕腎透析是由於預計的身體負累,只有百分之一點六接受腎臟紓緩治療會改變主義而接受腎透析。選擇腎透析和腎臟紓緩治療的病人在基本的身體狀況有明顯分別。生存率亦隨著修改版查爾森共病量表的分數而下降。年長、精神自主能力缺欠、高血脂、修改版查爾森共病量表分數高、腎小球濾過率低、白蛋白低均屬重要暨獨立的因素以預計較差的生存率。本文亦會探討在中國文化處境下影響預設照顧計劃討論的因素。

結論

有組織的預設照顧計劃討論能幫助病人在未期腎病的醫療方向作出知情的選擇。

背景/目的越来越多的人认识到需要将预先护理计划(ACP)整合到终末期肾病(ESRD)护理中,并关注医学、伦理、社会心理和精神问题,但比较选择肾脏替代疗法(RRT)和肾脏姑息治疗(RPC)患者的出版物很少。我们在这里分享我们在一个有肾脏替代和姑息治疗项目的中心对ESRD患者进行ACP治疗的经验。方法:从2006年6月到2011年12月,ESRD患者被授权在结构化ACP中对未来的医疗护理做出知情选择,强调这是一个持续的过程。选择RRT和RPC的患者分别在透析前诊所和一站式多学科RPC诊所进行随访。这是一项在二级护理医院进行的单中心研究。共纳入600例患者(265例RRT, 335例RPC),随访时间中位数为782天。结果大多数患者和家属因感觉身体负担而拒绝透析。只有1.6%的姑息治疗患者改变了他们的决定并开始透析。选择RRT或RPC的患者的基线特征不同。根据改良的Charlson合并症指数评分,生存率下降。年龄较大、精神障碍、高血脂、高修正Charlson合并症指数、低肾小球滤过率和低白蛋白是生存不良的重要独立预测因素。在中国文化背景下讨论了影响ACP决策的因素。ConclusionA结构化机场核心计划可以让病人做出明智决定ESRD的管理。背景於未期腎病患者的照顧中加入關注身心社靈和倫理問題的預設照顧計劃(ACP)受到日益重視,但有關比較接受腎替代療法和接受腎臟紓緩治療文獻討論為數不多。作為同時提供腎透析服務以及腎臟紓緩治療的部門,本文旨在分享我們為未期腎病者討論預計照顧計劃的經驗。方法自二零零六年六月至二零一零五月間,透過有組織的預設照顧計劃討論,未期腎病患者會被鼓勵就未來的治療計劃作出知情選擇。選擇腎透析和腎臟紓緩治療的病人會分別於透析預備門診和一站式跨科際腎臟紓緩治療門診去覆診。本研究於一家二級醫院進行。總共有六百病人參與此研究,當中265名接受腎透析,335名接受腎臟紓緩治療,其中位跟進日數為782日。結果大部份病人和家屬之所以拒絕腎透析是由於預計的身體負累,只有百分之一點六接受腎臟紓緩治療會改變主義而接受腎透析。選擇腎透析和腎臟紓緩治療的病人在基本的身體狀況有明顯分別。生存率亦隨著修改版查爾森共病量表的分數而下降。年長、精神自主能力缺欠、高血脂、修改版查爾森共病量表分數高、腎小球濾過率低、白蛋白低均屬重要暨獨立的因素以預計較差的生存率。本文亦會探討在中國文化處境下影響預設照顧計劃討論的因素。結論有組織的預設照顧計劃討論能幫助病人在未期腎病的醫療方向作出知情的選擇。
{"title":"Advance care planning for 600 Chinese patients with end-stage renal disease","authors":"Sze-Kit Yuen,&nbsp;Hay Ping Suen,&nbsp;Oi-Ling Kwok,&nbsp;Sai-Ping Yong,&nbsp;Man-Wah Tse","doi":"10.1016/j.hkjn.2016.04.001","DOIUrl":"10.1016/j.hkjn.2016.04.001","url":null,"abstract":"<div><h3>Background/purpose</h3><p>There is increasing recognition of the need to integrate advance care planning (ACP) into end-stage renal disease (ESRD) care with attention to medical, ethical, psychosocial, and spiritual issues but publications comparing patients who chose renal replacement therapy (RRT) and renal palliative care (RPC) is scarce. We here share our experience on ACP for ESRD patients in a center with renal replacement and palliative programs in place.</p></div><div><h3>Methods</h3><p>From June 2006 to December 2011, ESRD patients were empowered to make an informed choice of future medical care in a structured ACP that was emphasized to be an ongoing process. Patients who opted for RRT and RPC would be followed up at the predialysis clinic and the one-stop multidisciplinary RPC clinic, respectively. This was a single-center study in a secondary care hospital. A total of 600 patients (265 RRT, 335 RPC) were enrolled and followed up over a median of 782 days.</p></div><div><h3>Results</h3><p>The majority of patients and relatives declined dialysis because of perceived physical burden. Only 1.6% of palliative care patients changed their decision and commenced dialysis. Baseline characteristics differed between patients who chose RRT or RPC. Survival declined according to the modified Charlson Comorbidity Index scores. Older age, mental incompetence, hyperlipidemia, high modified Charlson Comorbidity Index, low estimated glomerular filtration rate, and low albumin were important independent predictors of poor survival. Factors affecting the ACP decision were discussed in the Chinese culture context.</p></div><div><h3>Conclusion</h3><p>A structured ACP could empower the patient to make an informed decision on the management of ESRD.</p></div><div><h3>背景</h3><p>於未期腎病患者的照顧中加入關注身心社靈和倫理問題的預設照顧計劃(ACP)受到日益重視,但有關比較接受腎替代療法和接受腎臟紓緩治療文獻討論為數不多。作為同時提供腎透析服務以及腎臟紓緩治療的部門,本文旨在分享我們為未期腎病者討論預計照顧計劃的經驗。</p></div><div><h3>方法</h3><p>自二零零六年六月至二零一零五月間,透過有組織的預設照顧計劃討論,未期腎病患者會被鼓勵就未來的治療計劃作出知情選擇。選擇腎透析和腎臟紓緩治療的病人會分別於透析預備門診和一站式跨科際腎臟紓緩治療門診去覆診。本研究於一家二級醫院進行。總共有六百病人參與此研究,當中265名接受腎透析,335名接受腎臟紓緩治療,其中位跟進日數為782日。</p></div><div><h3>結果</h3><p>大部份病人和家屬之所以拒絕腎透析是由於預計的身體負累,只有百分之一點六接受腎臟紓緩治療會改變主義而接受腎透析。選擇腎透析和腎臟紓緩治療的病人在基本的身體狀況有明顯分別。生存率亦隨著修改版查爾森共病量表的分數而下降。年長、精神自主能力缺欠、高血脂、修改版查爾森共病量表分數高、腎小球濾過率低、白蛋白低均屬重要暨獨立的因素以預計較差的生存率。本文亦會探討在中國文化處境下影響預設照顧計劃討論的因素。</p></div><div><h3>結論</h3><p>有組織的預設照顧計劃討論能幫助病人在未期腎病的醫療方向作出知情的選擇。</p></div>","PeriodicalId":100611,"journal":{"name":"Hong Kong Journal of Nephrology","volume":"19 ","pages":"Pages 19-27"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hkjn.2016.04.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77376941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Outcomes in elderly patients with end-stage renal disease: Comparison of renal replacement therapy and conservative management 老年终末期肾病患者的预后:肾脏替代治疗与保守治疗的比较
Pub Date : 2016-10-01 DOI: 10.1016/j.hkjn.2016.04.002
Wing-Hang Kwok, Sai-Ping Yong, Oi-Ling Kwok

Background/purpose

With global socioeconomic development and improvement in the general health care system, life expectancy increases, resulting in an increasing incidence of end-stage renal disease in the elderly population. We compared the survival rate in elderly patients aged  65 years with Stage 5 chronic kidney disease, managed with either renal replacement therapy (RRT) or conservative treatment. We also tried to identify factors associated with survival in these two groups.

Methods

This is a single-center retrospective study of patients aged  65 years with Stage 5 chronic kidney disease, who were referred to the nephrology team for renal advance care planning to assist in decision making for RRT or conservative treatment from 2005 to 2013. They were followed up till death or till December 31, 2014. Baseline characteristics (demographics, clinical data, functional status, socioeconomic factors, and laboratory parameters) and mortality data between the two groups were compared.

Results

A total of 558 patients were recruited during the study period, in which 126 (22.6%) patients opted for RRT and 432 (77.4%) for conservative treatment. Patients with less significant comorbidities, lower modified Charlson's Comorbidity Index scores, better functional and mental statuses, as well as better socioeconomic status were more likely to choose RRT. The RRT group had a longer median survival of 44.6 months compared with 10.0 months in the conservative treatment group. The survival advantage of the RRT group was lost in patients older than 85 years, or in those with high comorbidity (modified Charlson's Comorbidity Index score of ≥11) or dependent mobility. Age, comorbidity, and mobility were predictors of mortality in the RRT group. For the conservative group, age, mobility, and sex were predictors of mortality.

Conclusion

Elderly patients with end-stage renal disease can be benefited from RRT. However, the survival advantage of RRT was lost in very-advanced-age patients older than 85 years of age, in those with high comorbidity, or in functionally dependent patients.

目的

在全球性的社會經濟發展下;預期壽命得以延長;導致在老年人口中;末期腎病的發生率亦有所增長。我們在 ≥ 65 歲的第 5 期慢性腎病年老患者間;比較了腎置換療法 (RRT) 與保守療法所達到的存活率。同時;我們亦嘗試找出影響這兩組病人存活的因素。

方法

這是一項單中心的回溯性研究;對象為 ≥ 65 歲的第 5 期慢性腎病患者。他們是在 2005 年至 2013 年期間;被轉介至腎科團隊接受預設照顧計劃;以協助他們選擇 RRT 或保守療法;追蹤期至 2014 年 12 月 31 日或病人去世為止。我們比較了兩組病人的基線特徵及死亡率數據。

結果

本研究共納入 558 位病人;其中 126 (22.6%) 人選擇了 RRT;432 (77.4%) 人選擇了保守療法。RRT 組的存活中位數為 44.6 個月;較保守療法組的 10.0 個月長。然而;在 >85 歲、共病顯著 (mCCI ≥ 11)、或不能獨立行動的病人中;RRT 的存活優勢消失。在 RRT 組中;年齡、共病、及行動力是死亡的預測因子,在保守療法組中;年齡、行動力、及性別是死亡的預測因子。

結論

年老末期腎病患者可以獲益於 RRT,然而;在 >85 歲的極高齡者、共病顯著者、或不能獨立行動的病人中;RRT 的存活優勢不復存在。

背景/目的随着全球社会经济的发展和一般医疗保健系统的完善,预期寿命增加,导致老年人群终末期肾脏疾病的发病率增加。我们比较了年龄≥65岁的5期慢性肾脏疾病老年患者的生存率,这些患者接受肾脏替代疗法(RRT)或保守治疗。我们也试图在这两组中确定与生存相关的因素。方法本研究是一项单中心回顾性研究,纳入了2005 - 2013年间,年龄≥65岁的5期慢性肾脏疾病患者,这些患者被转至肾脏病组进行肾脏预先护理计划,以协助决定是否进行RRT或保守治疗。随访至死亡或至2014年12月31日。比较两组患者的基线特征(人口统计学、临床数据、功能状态、社会经济因素和实验室参数)和死亡率数据。结果研究期间共纳入558例患者,其中126例(22.6%)患者选择RRT, 432例(77.4%)患者选择保守治疗。合并症不显著、改良Charlson合并症指数评分较低、功能和精神状态较好以及社会经济地位较好的患者更有可能选择RRT。RRT组的中位生存期为44.6个月,而保守治疗组的中位生存期为10.0个月。RRT组的生存优势在85岁以上的患者、高合并症(改良Charlson合并症指数评分≥11)或依赖活动能力的患者中消失。年龄、合并症和活动能力是RRT组死亡率的预测因子。对于保守组,年龄、流动性和性别是死亡率的预测因子。结论老年终末期肾病患者可从RRT中获益。然而,RRT的生存优势在年龄大于85岁的高龄患者、高合并症患者或功能依赖患者中丧失。我們在≥65歲的第5期慢性腎病年老患者間;比較了腎置換療法(RRT)與保守療法所達到的存活率。同時;我們亦嘗試找出影響這兩組病人存活的因素。方法這是一項單中心的回溯性研究,對象為≥65歲的第5期慢性腎病患者。他們是在2005年至2013年期間;被轉介至腎科團隊接受預設照顧計劃;以協助他們選擇RRT或保守療法;追蹤期至2014年12月31日或病人去世為止。我們比較了兩組病人的基線特徵及死亡率數據。結果本研究共納入558位病人;其中126(22.6%)人選擇了RRT; 432(77.4%)人選擇了保守療法。RRT組的存活中位數為44.6個月;較保守療法組的10.0個月長。然而,在祝辞85歲,共病顯著(移动≥11),或不能獨立行動的病人中;RRT的存活優勢消失。在RRT組中;年齡,共病,及行動力是死亡的預測因子,在保守療法組中;年齡,行動力,及性別是死亡的預測因子。結論年老末期腎病患者可以獲益於RRT,然而,在在85年歲的極高齡者,共病顯著者,或不能獨立行動的病人中;RRT的存活優勢不復存在。
{"title":"Outcomes in elderly patients with end-stage renal disease: Comparison of renal replacement therapy and conservative management","authors":"Wing-Hang Kwok,&nbsp;Sai-Ping Yong,&nbsp;Oi-Ling Kwok","doi":"10.1016/j.hkjn.2016.04.002","DOIUrl":"10.1016/j.hkjn.2016.04.002","url":null,"abstract":"<div><h3>Background/purpose</h3><p>With global socioeconomic development and improvement in the general health care system, life expectancy increases, resulting in an increasing incidence of end-stage renal disease in the elderly population. We compared the survival rate in elderly patients aged<!--> <!-->≥<!--> <!-->65 years with Stage 5 chronic kidney disease, managed with either renal replacement therapy (RRT) or conservative treatment. We also tried to identify factors associated with survival in these two groups.</p></div><div><h3>Methods</h3><p>This is a single-center retrospective study of patients aged<!--> <!-->≥<!--> <!-->65 years with Stage 5 chronic kidney disease, who were referred to the nephrology team for renal advance care planning to assist in decision making for RRT or conservative treatment from 2005 to 2013. They were followed up till death or till December 31, 2014. Baseline characteristics (demographics, clinical data, functional status, socioeconomic factors, and laboratory parameters) and mortality data between the two groups were compared.</p></div><div><h3>Results</h3><p>A total of 558 patients were recruited during the study period, in which 126 (22.6%) patients opted for RRT and 432 (77.4%) for conservative treatment. Patients with less significant comorbidities, lower modified Charlson's Comorbidity Index scores, better functional and mental statuses, as well as better socioeconomic status were more likely to choose RRT. The RRT group had a longer median survival of 44.6 months compared with 10.0 months in the conservative treatment group. The survival advantage of the RRT group was lost in patients older than 85 years, or in those with high comorbidity (modified Charlson's Comorbidity Index score of ≥11) or dependent mobility. Age, comorbidity, and mobility were predictors of mortality in the RRT group. For the conservative group, age, mobility, and sex were predictors of mortality.</p></div><div><h3>Conclusion</h3><p>Elderly patients with end-stage renal disease can be benefited from RRT. However, the survival advantage of RRT was lost in very-advanced-age patients older than 85 years of age, in those with high comorbidity, or in functionally dependent patients.</p></div><div><h3>目的</h3><p>在全球性的社會經濟發展下;預期壽命得以延長;導致在老年人口中;末期腎病的發生率亦有所增長。我們在 ≥ 65 歲的第 5 期慢性腎病年老患者間;比較了腎置換療法 (RRT) 與保守療法所達到的存活率。同時;我們亦嘗試找出影響這兩組病人存活的因素。</p></div><div><h3>方法</h3><p>這是一項單中心的回溯性研究;對象為 ≥ 65 歲的第 5 期慢性腎病患者。他們是在 2005 年至 2013 年期間;被轉介至腎科團隊接受預設照顧計劃;以協助他們選擇 RRT 或保守療法;追蹤期至 2014 年 12 月 31 日或病人去世為止。我們比較了兩組病人的基線特徵及死亡率數據。</p></div><div><h3>結果</h3><p>本研究共納入 558 位病人;其中 126 (22.6%) 人選擇了 RRT;432 (77.4%) 人選擇了保守療法。RRT 組的存活中位數為 44.6 個月;較保守療法組的 10.0 個月長。然而;在 &gt;85 歲、共病顯著 (mCCI ≥ 11)、或不能獨立行動的病人中;RRT 的存活優勢消失。在 RRT 組中;年齡、共病、及行動力是死亡的預測因子,在保守療法組中;年齡、行動力、及性別是死亡的預測因子。</p></div><div><h3>結論</h3><p>年老末期腎病患者可以獲益於 RRT,然而;在 &gt;85 歲的極高齡者、共病顯著者、或不能獨立行動的病人中;RRT 的存活優勢不復存在。</p></div>","PeriodicalId":100611,"journal":{"name":"Hong Kong Journal of Nephrology","volume":"19 ","pages":"Pages 42-56"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hkjn.2016.04.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77640534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Reflections on the Hong Kong Journal of Nephrology 1999–2016 1999-2016《香港肾脏病学杂志》的思考
Pub Date : 2016-10-01 DOI: 10.1016/j.hkjn.2016.08.008
Philip Kam Tao Li
{"title":"Reflections on the Hong Kong Journal of Nephrology 1999–2016","authors":"Philip Kam Tao Li","doi":"10.1016/j.hkjn.2016.08.008","DOIUrl":"10.1016/j.hkjn.2016.08.008","url":null,"abstract":"","PeriodicalId":100611,"journal":{"name":"Hong Kong Journal of Nephrology","volume":"19 ","pages":"Pages A13-A15"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hkjn.2016.08.008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73275826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bleeding post-transplantation intrarenal pseudoaneurysms 肾内假性动脉瘤移植后出血
Pub Date : 2016-10-01 DOI: 10.1016/j.hkjn.2016.06.001
Ho Kwan Ken Sin , Samuel Ka Shun Fung , Hon Lok Tang , Au Cheuk , William Lee , Ka Fai Yim , Ka Yan Poon , Lok Yan Wong , Hiu Man Cheng

We herein present a case of an intrarenal pseudoaneurysm developing 2 weeks after renal transplantation. The patient presented with hemorrhagic shock. Computed tomography confirmed an intrarenal pseudoaneurysm with extravasation of contrast and a large surrounding hematoma. Angiography confirmed the pseudoaneurysm, and embolization of the segmental graft renal artery was performed. In view of the uncertain etiology and the possibility of a mycotic pseudoaneurysm, we administered empiric antimicrobial therapy. The clinical course, investigations, and management are described. Finally, a review of the literature regarding post-transplantation pseudoaneurysms is presented.

以下是一宗於移植後 2 週出現的腎內僞動脈瘤個案,患者以出血性休克表現。當時為其安排緊急電腦斷層攝影 (CT),發現有一個腎內僞動脈瘤,並呈現顯影劑溢出現象,且被一大型血腫圍繞。緊急血管攝影證實為植入腎之僞動脈瘤,同時我們對涉及的節段性動脈予以栓塞處置。基於病因並不明確,而且不能排除黴菌性僞動脈瘤的可能性,因此我們實施了經驗性抗微生物學療法。在本文中,我們描述了本個案的臨床歷程、相關檢查及後續處置,並指出我們在治療上所遭遇到的困難。最後,我們對移植後僞動脈瘤的相關文獻作出了回顧。

We herein present a case of an intrarenal pseudoaneurysm developing 2 weeks after renal transplantation. The patient presented with hemorrhagic shock. Computed tomography confirmed an intrarenal pseudoaneurysm with extravasation of contrast and a large surrounding hematoma. Angiography confirmed the pseudoaneurysm, and embolization of the segmental graft renal artery was performed. In view of the uncertain etiology and the possibility of a mycotic pseudoaneurysm, we administered empiric antimicrobial therapy. The clinical course, investigations, and management are described. Finally, a review of the literature regarding post-transplantation pseudoaneurysms is presented.以下是一宗于移植后 2 周出现的肾内伪动脉瘤个案,患者以出血性休克表现。当时为其安排紧急电脑断层摄影 (CT),发现有一个肾内伪动脉瘤,并呈现显影剂溢出现象,且被一大型血肿围绕。紧急血管摄影证实为植入肾之伪动脉瘤,同时我们对涉及的节段性动脉予以栓塞处置。基于病因并不明确,而且不能排除霉菌性伪动脉瘤的可能性,因此我们实施了经验性抗微生物学疗法。在本文中,我们描述了本个案的临床历程、相关检查及后续处置,并指出我们在治疗上所遭遇到的困难。最后,我们对移植后伪动脉瘤的相关文献作出了回顾。
{"title":"Bleeding post-transplantation intrarenal pseudoaneurysms","authors":"Ho Kwan Ken Sin ,&nbsp;Samuel Ka Shun Fung ,&nbsp;Hon Lok Tang ,&nbsp;Au Cheuk ,&nbsp;William Lee ,&nbsp;Ka Fai Yim ,&nbsp;Ka Yan Poon ,&nbsp;Lok Yan Wong ,&nbsp;Hiu Man Cheng","doi":"10.1016/j.hkjn.2016.06.001","DOIUrl":"10.1016/j.hkjn.2016.06.001","url":null,"abstract":"<div><p>We herein present a case of an intrarenal pseudoaneurysm developing 2 weeks after renal transplantation. The patient presented with hemorrhagic shock. Computed tomography confirmed an intrarenal pseudoaneurysm with extravasation of contrast and a large surrounding hematoma. Angiography confirmed the pseudoaneurysm, and embolization of the segmental graft renal artery was performed. In view of the uncertain etiology and the possibility of a mycotic pseudoaneurysm, we administered empiric antimicrobial therapy. The clinical course, investigations, and management are described. Finally, a review of the literature regarding post-transplantation pseudoaneurysms is presented.</p><p>以下是一宗於移植後 2 週出現的腎內僞動脈瘤個案,患者以出血性休克表現。當時為其安排緊急電腦斷層攝影 (CT),發現有一個腎內僞動脈瘤,並呈現顯影劑溢出現象,且被一大型血腫圍繞。緊急血管攝影證實為植入腎之僞動脈瘤,同時我們對涉及的節段性動脈予以栓塞處置。基於病因並不明確,而且不能排除黴菌性僞動脈瘤的可能性,因此我們實施了經驗性抗微生物學療法。在本文中,我們描述了本個案的臨床歷程、相關檢查及後續處置,並指出我們在治療上所遭遇到的困難。最後,我們對移植後僞動脈瘤的相關文獻作出了回顧。</p></div>","PeriodicalId":100611,"journal":{"name":"Hong Kong Journal of Nephrology","volume":"19 ","pages":"Pages 57-60"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hkjn.2016.06.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73828047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in peritoneal membrane with different peritoneal dialysis solutions: Is there a difference? 不同腹膜透析液对腹膜的改变:有区别吗?
Pub Date : 2016-10-01 DOI: 10.1016/j.hkjn.2016.03.001
Abdullah Khalaf Al-Hwiesh , Mohamed A. Shawarby , Ibrahiem Saeed Abdul-Rahman , Nadia Al-Oudah , Bander Al-Dhofairy , Jose Carolino Divino-Filho , Abdalla Abdelrahman , Hazem Zakaria , Mohammad A. Nasr El-Din , Ahmed Eldamati , Tamer El-Salamony , Fahd A. Al-Muhanna

Background/Purpose

The peritoneal membrane of long-term peritoneal dialysis (PD) patients is characterized by morphological and microvascular changes. It is said that lactate-based peritoneal dialysate is implicated in the development of these changes. The aim of this study is to compare the effects of long-term exposure to glucose-based, lactate-buffered (Dianeal), and biocompatible bicarbonate/lactate-buffered, low glucose degradation product (Physioneal) peritoneal solutions on the peritoneal membrane.

Methods

Thirty-nine incident PD patients were randomized into two groups: 19 patients with Dianeal dialysate (Group A) and 20 with biocompatible Physioneal dialysate (Group B). All patients used automated PD for a median of 31 months in Group A and 32 months in Group B. Three biopsies at one occasion only were taken from the peritoneal membrane at the end of the study. All samples were collected and fixed in accordance with a standardized protocol, and a histopathologist blinded to the clinical status and PD solutions allocated to the patients carried out the analysis.

Results

The commonest change observed was peritoneal fibrosis, seen in 35 out of 39 cases (89.7%); it was moderate to severe in 28 cases (71.8%) and mild in 11 (28.2%) cases. This was followed by loss of mesothelial cells (22 cases, 56.4%), elastosis (20 cases, 51.3%), increased blood vessels (15 cases, 38.5%), thick-walled blood vessels (10 cases, 25.6%), and finally chronic inflammation and mesothelial cell hyperplasia (7 cases, 17.9%, and 6 cases, 15.4%, respectively). Of the patients with blood vessel abnormalities, 22 (88.0%) exhibited significant fibrosis and only three (12.0%) did not. Of those without blood vessel changes, only six (42.9%) patients exhibited similar degree of fibrosis (p < 0.01). The prevalence of vascular changes, moderate to severe fibrosis, as well as mesothelial cell abnormalities increased as the duration of PD increased. The prevalence of fibrosis, mesothelial cell loss, and vascular abnormalities increased significantly with diabetes mellitus (p < 0.001).

Conclusion

There was no difference in the effects of long-term exposure to glucose-based, lactate-buffered, and biocompatible bicarbonate/lactate-buffered, low glucose degradation product peritoneal solutions on the peritoneal membrane. Risk factors other than PD dialysate composition need to be considered when assessing peritoneal membrane adequacy. The factors that were proved to be significant in our study are duration of end-stage renal disease, diabetes mellitus, and time on PD.

背景 / 目的

在接受長期腹膜透析 (PD) 的病人間,腹膜會出現若干的形態學與微血管變化,這些變化被認為與採用乳酸鹽腹膜透析液有關。本研究旨在比較兩種透析液的長期暴露—乳酸鹽緩衝之 Dianeal®、與生物相容之 Physioneal® 對病人腹膜的影響。

方法

共 39 位剛開始接受 PD 的病人被分為兩組:19 人接受 Dianeal 透析液 (A 組)、20 人接受生物相容之 Physioneal 透析液 (B 組),所有病人接受的均為自動化 PD (APD

背景/目的长期腹膜透析(PD)患者的腹膜以形态和微血管改变为特征。据说,以乳酸为基础的腹膜透析液与这些变化的发生有关。本研究的目的是比较长期暴露于葡萄糖基乳酸缓冲溶液(dieal)和生物相容性碳酸氢盐/乳酸缓冲低糖降解产物(Physioneal)腹膜溶液对腹膜的影响。方法39例PD患者随机分为两组:19例患者使用dinal透析液(A组),20例患者使用生物相容性Physioneal透析液(B组)。所有患者均使用自动PD, A组中位时间为31个月,B组中位时间为32个月。研究结束时,仅在一次腹膜上进行了3次活检。所有样本按照标准化方案收集并固定,由组织病理学家对临床状态和分配给患者的PD溶液进行盲法分析。结果39例患者中最常见的改变是腹膜纤维化,占35例(89.7%);中度至重度28例(71.8%),轻度11例(28.2%)。其次是间皮细胞缺失(22例,56.4%)、弹性增生(20例,51.3%)、血管增生(15例,38.5%)、厚壁血管(10例,25.6%),最后是慢性炎症和间皮细胞增生(分别为7例,17.9%和6例,15.4%)。在血管异常的患者中,22例(88.0%)表现出明显的纤维化,只有3例(12.0%)没有。在没有血管改变的患者中,只有6名(42.9%)患者表现出类似程度的纤维化(p <0.01)。随着PD持续时间的增加,血管改变、中重度纤维化以及间皮细胞异常的发生率增加。糖尿病患者纤维化、间皮细胞丢失和血管异常的发生率显著增加(p <0.001)。结论长期暴露于葡萄糖基、乳酸缓冲和生物相容性碳酸氢盐/乳酸缓冲低糖降解产物腹膜溶液对腹膜的影响无差异。在评估腹膜充分性时,需要考虑PD透析液成分以外的危险因素。在我们的研究中被证明是重要的因素是终末期肾脏疾病的持续时间,糖尿病和PD的时间。背景/目的在接受長期腹膜透析(PD)的病人間,腹膜會出現若干的形態學與微血管變化,這些變化被認為與採用乳酸鹽腹膜透析液有關。本研究旨在比較兩種透析液的長期暴露——乳酸鹽緩衝之Dianeal®,與生物相容之Physioneal®對病人腹膜的影響。方法共39位剛開始接受PD的病人被分為兩組:19人接受Dianeal透析液(組),20人接受生物相容之Physioneal透析液(B組)所有病人接受的均為自動化PD (adp)。研究結束時,我們對病人腹膜進行了活組織檢驗。結果在一个組及B組之間,間皮細胞消失分別發生於52.6%及60.0%的病人,間皮細胞增生則分別發生於21.1%及15.0%的病人(p比;0.05);嚴重間質纖維化分別發生於42.1%及45.0%的病人,中度間質纖維化則分別發生於31.6%及25.0%的病人(p比;0.05)。在一个組及B組的病人之間,彈性組織變性(弹性组织变性)達到“3 +”的比率分別為15.8%及20.0%,達到“2 +”的比率分別為15.8%及15.0% (p比;(p > p >0.05)。【中文翻译】:p <0.001)。結論長期採用以上兩種腹膜透析液於PD病人中,並未導致不同的腹膜變化。“”“”“”“”“”“”“”。
{"title":"Changes in peritoneal membrane with different peritoneal dialysis solutions: Is there a difference?","authors":"Abdullah Khalaf Al-Hwiesh ,&nbsp;Mohamed A. Shawarby ,&nbsp;Ibrahiem Saeed Abdul-Rahman ,&nbsp;Nadia Al-Oudah ,&nbsp;Bander Al-Dhofairy ,&nbsp;Jose Carolino Divino-Filho ,&nbsp;Abdalla Abdelrahman ,&nbsp;Hazem Zakaria ,&nbsp;Mohammad A. Nasr El-Din ,&nbsp;Ahmed Eldamati ,&nbsp;Tamer El-Salamony ,&nbsp;Fahd A. Al-Muhanna","doi":"10.1016/j.hkjn.2016.03.001","DOIUrl":"10.1016/j.hkjn.2016.03.001","url":null,"abstract":"<div><h3>Background/Purpose</h3><p>The peritoneal membrane of long-term peritoneal dialysis (PD) patients is characterized by morphological and microvascular changes. It is said that lactate-based peritoneal dialysate is implicated in the development of these changes. The aim of this study is to compare the effects of long-term exposure to glucose-based, lactate-buffered (Dianeal), and biocompatible bicarbonate/lactate-buffered, low glucose degradation product (Physioneal) peritoneal solutions on the peritoneal membrane.</p></div><div><h3>Methods</h3><p>Thirty-nine incident PD patients were randomized into two groups: 19 patients with Dianeal dialysate (Group A) and 20 with biocompatible Physioneal dialysate (Group B). All patients used automated PD for a median of 31 months in Group A and 32 months in Group B. Three biopsies at one occasion only were taken from the peritoneal membrane at the end of the study. All samples were collected and fixed in accordance with a standardized protocol, and a histopathologist blinded to the clinical status and PD solutions allocated to the patients carried out the analysis.</p></div><div><h3>Results</h3><p>The commonest change observed was peritoneal fibrosis, seen in 35 out of 39 cases (89.7%); it was moderate to severe in 28 cases (71.8%) and mild in 11 (28.2%) cases. This was followed by loss of mesothelial cells (22 cases, 56.4%), elastosis (20 cases, 51.3%), increased blood vessels (15 cases, 38.5%), thick-walled blood vessels (10 cases, 25.6%), and finally chronic inflammation and mesothelial cell hyperplasia (7 cases, 17.9%, and 6 cases, 15.4%, respectively). Of the patients with blood vessel abnormalities, 22 (88.0%) exhibited significant fibrosis and only three (12.0%) did not. Of those without blood vessel changes, only six (42.9%) patients exhibited similar degree of fibrosis (<em>p</em> &lt; 0.01). The prevalence of vascular changes, moderate to severe fibrosis, as well as mesothelial cell abnormalities increased as the duration of PD increased. The prevalence of fibrosis, mesothelial cell loss, and vascular abnormalities increased significantly with diabetes mellitus (<em>p</em> &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>There was no difference in the effects of long-term exposure to glucose-based, lactate-buffered, and biocompatible bicarbonate/lactate-buffered, low glucose degradation product peritoneal solutions on the peritoneal membrane. Risk factors other than PD dialysate composition need to be considered when assessing peritoneal membrane adequacy. The factors that were proved to be significant in our study are duration of end-stage renal disease, diabetes mellitus, and time on PD.</p></div><div><h3>背景 / 目的</h3><p>在接受長期腹膜透析 (PD) 的病人間,腹膜會出現若干的形態學與微血管變化,這些變化被認為與採用乳酸鹽腹膜透析液有關。本研究旨在比較兩種透析液的長期暴露—乳酸鹽緩衝之 Dianeal<sup>®</sup>、與生物相容之 Physioneal<sup>®</sup> 對病人腹膜的影響。</p></div><div><h3>方法</h3><p>共 39 位剛開始接受 PD 的病人被分為兩組:19 人接受 Dianeal 透析液 (A 組)、20 人接受生物相容之 Physioneal 透析液 (B 組),所有病人接受的均為自動化 PD (APD","PeriodicalId":100611,"journal":{"name":"Hong Kong Journal of Nephrology","volume":"19 ","pages":"Pages 7-18"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hkjn.2016.03.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87883325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Pharmacokinetic study of once-daily formulation of tacrolimus (Advagraf) in stable Chinese kidney transplant recipients 他克莫司(Advagraf)在稳定肾移植受者体内的药代动力学研究
Pub Date : 2016-10-01 DOI: 10.1016/j.hkjn.2016.03.002
Terry King-Wing Ma, Kai Ming Chow, Phyllis Mei-Shan Cheng, Bonnie Ching-Ha Kwan, Chi Bon Leung, Philip Kam-Tao Li, Cheuk Chun Szeto

Background/Purpose

The objective of this study is to determine whether tacrolimus trough level is appropriate for therapeutic drug monitoring (TDM) of Advagraf in stable Chinese kidney transplant recipients (KTRs).

Methods

In this single-center pharmacokinetic study, stable adult Chinese KTRs on Advagraf were recruited and their blood tacrolimus levels measured at 12 time points within 24 hours. Trough level was defined as predose drug level (C0). The pharmacokinetic parameters were calculated using standardized noncompartmental methods. Drug exposure, defined as 24-hour area under the curve (AUC0–24), was calculated using the linear trapezoidal method. Whole blood tacrolimus level measurement was performed by high-performance liquid chromatography/tandem mass spectrophotometry.

Results

Fourteen patients (8 males; mean age, 47.1 ± 9.2 years; mean duration of transplant, 8.3 ± 3.6 years) completed the study. The mean C0 was 4.4 ± 1.9 ng/mL, and the mean AUC0–24 was 143.8 ± 57.0 ng h/mL. The mean maximum concentration (Cmax) was 10.2 ± 3.9 ng/mL, and the median time to Cmax was 2.0 hours (interquartile range, 1.0–3.0 hours). There was a strong correlation between C0 and AUC0–24 (r = 0.90, p < 0.001). Patients receiving diltiazem had higher mean AUC0–24 (153.0 ± 55.3 ng h/mL vs. 110.1 ± 60.1 ng h/mL) despite a lower dose (mean tacrolimus dose, 0.039 ± 0.022 mg/kg/d vs. 0.054 ± 0.021 mg/kg/d), although both differences did not reach statistical significance. Apart from C0, tacrolimus level obtained from 6 hours to 12 hours (C6 to C12) also had good correlation with AUC0–24.

Conclusion

Tacrolimus trough level is a good surrogate marker for TDM of Advagraf in stable Chinese KTRs. The role of C6 to C12 in TDM remains to be determined.

背景 / 目的

本研究旨在調查在病情穩定的華裔腎臟移植接受者 (KTRs) 間,Cmin 是否適用於藥物血中濃度監測 (TDM)。

方法

在這一項單中心藥物動力學研究中,對象為病情穩定的華裔 KTRs,在 24 小時內 12 個時間點接受了動脈血的取樣,谷值的定義為服藥前藥物濃度 (C0)。藥物動力學參數的計算是採用標準化無房室模式,AUC0–24 的計算採用線性梯形方式。全血 tacrolimus 濃度的測量儀器,則是採用高效能液相色層分析串聯質譜儀 (HPLCMS/MS)。

結果

本研究共納入 14 位服用 Advagraf® 的病人,平均 C0 為 4.4 ± 1.9 ng/ml,平均 AUC0–24 為 143.8 ± 57.0 ng·h/ml,平均最高濃度 Cmax 為 10.2 ± 3.9 ng/ml,達到 Cmax 的時間中位數 tmax 則為 2.0 小時 (四分位數間距 1.0–3.0 小時);C0 與 AUC0–24 存在明顯的相關性 (r = 0.90、p < 0.001)。在接受 diltiazem 的病人中,平均 AUC0–24 較高 (153.0 ± 55.3 ng·h/ml vs. 110.1 ± 60.1 ng·h/ml),即使他們服用較低的 tacrolimus 劑量 (平均劑量 0.039 ± 0.022 mg/kg/day vs. 0.054 ± 0.021 mg/kg/day);這兩種差異未達統計學意義。除了 C0 之外,6 至 12 小時 (C6 to C12) 之 tacrolimus 濃度亦與 AUC0–24 存在顯著的相關性。

結論

對於病情穩定的華裔 KTRs,tacrolimus 谷值乃 AUC0–24 的一個

背景/目的本研究的目的是确定他克莫司谷底水平是否适合用于稳定的中国肾移植受者(KTRs)的Advagraf治疗药物监测(TDM)。方法在单中心药代动力学研究中,招募服用Advagraf的稳定的中国成年KTRs,在24小时内的12个时间点测量其血液他克莫司水平。谷水平定义为给药前药物水平(C0)。采用标准化非区室法计算药代动力学参数。药物暴露量定义为24小时曲线下面积(AUC0-24),采用线性梯形法计算。采用高效液相色谱-串联质谱法测定全血他克莫司水平。结果14例患者(男8例;平均年龄47.1±9.2岁;平均移植时间8.3±3.6年)完成研究。平均C0为4.4±1.9 ng/mL,平均AUC0-24为143.8±57.0 ng h/mL。平均最大浓度(Cmax)为10.2±3.9 ng/mL,达到Cmax的中位时间为2.0 h(四分位数间距为1.0 ~ 3.0 h)。C0与AUC0-24有很强的相关性(r = 0.90, p <0.001)。地尔硫卓患者的平均AUC0-24(153.0±55.3 ng h/mL vs. 110.1±60.1 ng h/mL)尽管剂量较低(他克莫司平均剂量,0.039±0.022 mg/kg/d vs. 0.054±0.021 mg/kg/d),但两者差异均无统计学意义。除C0外,6 ~ 12小时(C6 ~ C12)他克莫司浓度也与AUC0-24有良好的相关性。结论他克莫司谷水平是中国稳定ktr患者较好的TDM替代指标。C6至C12在TDM中的作用仍有待确定。背景/目的本研究旨在調查在病情穩定的華裔腎臟移植接受者城(KTRs)間Cmin是否適用於藥物血中濃度監測(TDM)。方法在這一項單中心藥物動力學研究中,對象為病情穩定的華城裔KTRs,在24小時內12個時間點接受了動脈血的取樣,谷值的定義為服藥前藥物濃度(C0)。藥物動力學參數的計算是採用標準化無房室模式,AUC0-24的計算採用線性梯形方式。全血他克莫司濃度的測量儀器,則是採用高效能液相色層分析串聯質譜儀(HPLCMS / MS)。結果本研究共納入14位服用Advagraf®的病人,平均C0為4.4±1.9 ng / ml,平均AUC0-24為·h 143.8±57.0 ng / ml,平均最高濃度Cmax為10.2±3.9 ng / ml,達到Cmax的時間中位數达峰时间則為2.0小時(四分位數間距1.0 - -3.0小時);C0與AUC0-24存在明顯的相關性(r = 0.90, p & lt;0.001)。在接受地尔硫卓的病人中,平均AUC0-24較高·h(153.0±55.3 ng / ml和110.1±60.1 ng·h /毫升),即使他們服用較低的他克莫司劑量(平均劑量0.039±0.022毫克/公斤/日和0.054±0.021毫克/公斤/天);這兩種差異未達統計學意義。除了C0之外,6至12小時(C12 C6)之他克莫司濃度亦與AUC0-24存在顯著的相關性。結論對於病情穩定的華城裔KTRs,他克莫司谷值乃AUC0-24的一個良好替代指標;至於C6, C12的角色則仍有待證實。
{"title":"Pharmacokinetic study of once-daily formulation of tacrolimus (Advagraf) in stable Chinese kidney transplant recipients","authors":"Terry King-Wing Ma,&nbsp;Kai Ming Chow,&nbsp;Phyllis Mei-Shan Cheng,&nbsp;Bonnie Ching-Ha Kwan,&nbsp;Chi Bon Leung,&nbsp;Philip Kam-Tao Li,&nbsp;Cheuk Chun Szeto","doi":"10.1016/j.hkjn.2016.03.002","DOIUrl":"10.1016/j.hkjn.2016.03.002","url":null,"abstract":"<div><h3>Background/Purpose</h3><p>The objective of this study is to determine whether tacrolimus trough level is appropriate for therapeutic drug monitoring (TDM) of Advagraf in stable Chinese kidney transplant recipients (KTRs).</p></div><div><h3>Methods</h3><p>In this single-center pharmacokinetic study, stable adult Chinese KTRs on Advagraf were recruited and their blood tacrolimus levels measured at 12 time points within 24 hours. Trough level was defined as predose drug level (<em>C</em><sub>0</sub>). The pharmacokinetic parameters were calculated using standardized noncompartmental methods. Drug exposure, defined as 24-hour area under the curve (AUC<sub>0–24</sub>), was calculated using the linear trapezoidal method. Whole blood tacrolimus level measurement was performed by high-performance liquid chromatography/tandem mass spectrophotometry.</p></div><div><h3>Results</h3><p>Fourteen patients (8 males; mean age, 47.1 ± 9.2 years; mean duration of transplant, 8.3 ± 3.6 years) completed the study. The mean <em>C</em><sub>0</sub> was 4.4 ± 1.9 ng/mL, and the mean AUC<sub>0–24</sub> was 143.8 ± 57.0 ng h/mL. The mean maximum concentration (<em>C</em><sub>max</sub>) was 10.2 ± 3.9 ng/mL, and the median time to <em>C</em><sub>max</sub> was 2.0 hours (interquartile range, 1.0–3.0 hours). There was a strong correlation between <em>C</em><sub>0</sub> and AUC<sub>0–24</sub> (<em>r</em> = 0.90, <em>p</em> &lt; 0.001). Patients receiving diltiazem had higher mean AUC<sub>0–24</sub> (153.0 ± 55.3 ng h/mL vs. 110.1 ± 60.1 ng h/mL) despite a lower dose (mean tacrolimus dose, 0.039 ± 0.022 mg/kg/d vs. 0.054 ± 0.021 mg/kg/d), although both differences did not reach statistical significance. Apart from <em>C</em><sub>0</sub>, tacrolimus level obtained from 6 hours to 12 hours (<em>C</em><sub>6</sub> to <em>C</em><sub>12</sub>) also had good correlation with AUC<sub>0–24</sub>.</p></div><div><h3>Conclusion</h3><p>Tacrolimus trough level is a good surrogate marker for TDM of Advagraf in stable Chinese KTRs. The role of <em>C</em><sub>6</sub> to <em>C</em><sub>12</sub> in TDM remains to be determined.</p></div><div><h3>背景 / 目的</h3><p>本研究旨在調查在病情穩定的華裔腎臟移植接受者 (KTRs) 間,Cmin 是否適用於藥物血中濃度監測 (TDM)。</p></div><div><h3>方法</h3><p>在這一項單中心藥物動力學研究中,對象為病情穩定的華裔 KTRs,在 24 小時內 12 個時間點接受了動脈血的取樣,谷值的定義為服藥前藥物濃度 (C0)。藥物動力學參數的計算是採用標準化無房室模式,AUC0–24 的計算採用線性梯形方式。全血 tacrolimus 濃度的測量儀器,則是採用高效能液相色層分析串聯質譜儀 (HPLCMS/MS)。</p></div><div><h3>結果</h3><p>本研究共納入 14 位服用 Advagraf<sup>®</sup> 的病人,平均 C0 為 4.4 ± 1.9 ng/ml,平均 AUC0–24 為 143.8 ± 57.0 ng·h/ml,平均最高濃度 Cmax 為 10.2 ± 3.9 ng/ml,達到 Cmax 的時間中位數 tmax 則為 2.0 小時 (四分位數間距 1.0–3.0 小時);C0 與 AUC0–24 存在明顯的相關性 (<em>r</em> = 0.90、<em>p</em> &lt; 0.001)。在接受 diltiazem 的病人中,平均 AUC0–24 較高 (153.0 ± 55.3 ng·h/ml vs. 110.1 ± 60.1 ng·h/ml),即使他們服用較低的 tacrolimus 劑量 (平均劑量 0.039 ± 0.022 mg/kg/day vs. 0.054 ± 0.021 mg/kg/day);這兩種差異未達統計學意義。除了 C0 之外,6 至 12 小時 (C6 to C12) 之 tacrolimus 濃度亦與 AUC0–24 存在顯著的相關性。</p></div><div><h3>結論</h3><p>對於病情穩定的華裔 KTRs,tacrolimus 谷值乃 AUC0–24 的一個","PeriodicalId":100611,"journal":{"name":"Hong Kong Journal of Nephrology","volume":"19 ","pages":"Pages 1-6"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hkjn.2016.03.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77291284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Hong Kong Journal of Nephrology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1